Otamixaban in acute coronary syndromes

The Lancet

Volumn 374, Issue 9692, 2009, Pages 762-764

  Eikelboom, John W ^a,b   Weitz, Jeffrey I ^b,c  

^a HAMILTON GENERAL HOSPITAL   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c HENDERSON RESEARCH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; APIXABAN; CLOPIDOGREL; EPTIFIBATIDE; FONDAPARINUX; HEPARIN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; OTAMIXABAN; PRASUGREL; RB 006; RIVAROXABAN; UNCLASSIFIED DRUG; WARFARIN;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG MECHANISM; HUMAN; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL;

EID: 69449098151     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)61529-4     Document Type: Note

References (11)

1. Guertin K.R., and Choi Y.M. The discovery of the factor Xa inhibitor otamixaban: from lead identification to clinical development. Curr Med Chem 14 (2007) 2471-2481
2. Cohen M., Bhatt D.L., Alexander J.H., et al., on behalf of the SEPIA-PCI Trial Investigators. Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention: the SEPIA-PCI trial. Circulation 115 (2007) 2642-2651
3. Sabatine M.S., Antman E.M., Widimsky P., et al. Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial. Lancet (2009) 10.1016/S0140-6736(09)61454-9 published online Aug 30.
4. Rusconi C.P., Scardino E., Layzer J., et al. RNA aptamers as reversible antagonists of coagulation factor IXa. Nature 419 (2002) 90-94
5. Dyke C.K., Steinhubl S.R., Kleiman N.S., et al. First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity. Circulation 114 (2006) 2490-2497
6. Chan M.Y., Cohen M.G., Dyke C.K., et al. Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease. Circulation 117 (2008) 2865-2874
7. Hurlen M., Abdelnoor M., Smith P., Erikssen J., and Arnesen H. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 347 (2002) 969-974
8. van Es R.F., Jonker J.J., Verheugt F.W., Deckers J.W., Grobbee D.E., and for the Antithrombotics in the Secondary Prevention of Events in Coronary Thrombosis-2 (ASPECT-2) Research Group. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet 360 (2002) 109-113
9. APPRAISE Steering Committee and Investigators. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation 119 (2009) 2877-2885
10. Mega J.L., Braunwald E., Mohanavelu S., et al., on behalf of the ATLAS ACS-TIMI 46 study group. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet 374 (2009) 29-38
11. Wiviott S.D., Braunwald E., McCabe C.H., et al., for the TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357 (2007) 2001-2015